Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
12.11
-0.24 (-1.94%)
At close: Jun 12, 2026, 4:00 PM EDT
12.67
+0.56 (4.62%)
Pre-market: Jun 15, 2026, 8:33 AM EDT
Intellia Therapeutics Employees
Intellia Therapeutics had 377 employees as of December 31, 2025. The number of employees decreased by 26 or -6.45% compared to the previous year.
Employees
377
Change (1Y)
-26
Growth (1Y)
-6.45%
Revenue / Employee
$175,310
Profits / Employee
-$1,046,674
Market Cap
1.69B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 377 | -26 | -6.45% |
| Dec 31, 2024 | 403 | -123 | -23.38% |
| Dec 31, 2023 | 526 | -72 | -12.04% |
| Dec 31, 2022 | 598 | 113 | 23.30% |
| Dec 31, 2021 | 485 | 173 | 55.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ascentage Pharma Group International | 767 |
| Recursion Pharmaceuticals | 600 |
| Agios Pharmaceuticals | 540 |
| Nurix Therapeutics | 317 |
| Nuvation Bio | 307 |
| Biohaven | 274 |
| Zymeworks | 243 |
| uniQure | 221 |
NTLA News
- 16 hours ago - Intellia Therapeutics presents additional results from Phase 3 HAELO trial - TheFly
- 2 days ago - Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - GlobeNewsWire
- 5 days ago - Intellia Therapeutics Transcript: AGM 2026 - Transcripts
- 9 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 11 days ago - Intellia Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 14 days ago - Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026 - GlobeNewsWire
- 25 days ago - Intellia Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Intellia Therapeutics price target raised to $17 from $13 at Bernstein - TheFly